Summary of Conference Call Company/Industry Involved - The conference call pertains to Huazhong Securities Research Institute, specifically addressing its whitelist clients [1] Core Points and Arguments - The call emphasizes that it does not constitute investment advice for participants [1] - Participants are reminded to make independent investment decisions and bear their own investment risks [1] - Huazhong Securities disclaims any responsibility for losses incurred by individuals using the content of the meeting [1] Other Important but Possibly Overlooked Content - The call is governed by the Securities and Futures Investor Suitability Management Measures, indicating regulatory compliance [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The report indicates that the company's performance meets expectations, entering a new high-quality development cycle [2] - The company achieved a revenue of 1.471 billion yuan in 2023, representing a year-on-year increase of 27.20%, and a net profit attributable to shareholders of 100 million yuan, up 116.85% year-on-year [2][5] - The dual-driven strategy of medical services and medical devices is expected to drive high growth, with projected revenues of 1.765 billion, 2.048 billion, and 2.429 billion yuan for 2024, 2025, and 2026 respectively, reflecting year-on-year growth rates of 20.0%, 16.0%, and 18.6% [5][11] Summary by Sections Financial Performance - In 2023, the company reported a gross margin of 28.57%, an increase of 2.04 percentage points year-on-year, and an operating cash flow of 190 million yuan, up 18.26% year-on-year [2] - The medical services segment generated revenue of 1.149 billion yuan, a year-on-year increase of 15.28%, while the medical devices segment saw revenue of 322 million yuan, up 101.69% year-on-year [2] Business Segments - The medical services segment focuses on building a tumor specialty system, with significant revenue contributions from hospitals such as Sichuan Friendship Hospital and Suzhou Guangci Hospital [2] - The medical devices segment has rapidly expanded, supported by acquisitions and increased R&D investment, which reached 52 million yuan, up 86.35% year-on-year [2][5] Future Projections - The company is expected to maintain robust growth in both segments, with net profit projections of 126 million, 154 million, and 197 million yuan for 2024, 2025, and 2026 respectively, indicating year-on-year growth rates of 25.2%, 22.1%, and 28.5% [5][11]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5][13]. Core Views - The company has achieved rapid growth in revenue and profit, with a notable increase in profitability, indicating a high-quality development phase [3][4]. - The medical services and medical devices sectors have both performed well, showcasing a trend towards high-quality development [3][4]. - The company is focused on building a comprehensive ecosystem for cancer treatment, integrating medical services and medical devices to drive growth [5][18]. Financial Performance - In 2023, the company reported a revenue of 1.471 billion yuan, representing a year-on-year increase of 27.20%, and a net profit attributable to shareholders of 100.44 million yuan, up 116.85% [3][6]. - Quarterly revenue for 2023 showed consistent growth: Q1 at 361 million yuan (+35.09%), Q2 at 362 million yuan (+17.91%), Q3 at 380 million yuan (+31.64%), and Q4 at 367 million yuan (+25.40%) [3]. - The gross margin for 2023 was 28.57%, an increase of 2.04 percentage points, while the net margin stood at 6.74% [3][6]. Segment Performance - The medical services segment generated revenue of 1.149 billion yuan (+15.25%) in 2023, with a gross margin of 24.82% [3][4]. - The medical devices segment saw significant growth, achieving revenue of 322 million yuan (+101.69%) with a gross margin of 41.97% [3][4]. Future Projections - Revenue projections for 2024 to 2026 are estimated at 1.770 billion yuan, 2.129 billion yuan, and 2.564 billion yuan, respectively, with corresponding net profits of 125.92 million yuan, 176.80 million yuan, and 256.87 million yuan [5][6]. - The company is expected to maintain a strong growth trajectory, with a projected P/E ratio decreasing from 47.12 in 2023 to 18.43 by 2026 [6][19].

Summary of Conference Call Company/Industry Involved - The conference call pertains to Huazhong Securities Research Institute, specifically addressing its whitelist clients [1] Core Points and Arguments - The call emphasizes that it does not constitute investment advice for participants [1] - Participants are reminded to make independent investment decisions and bear their own investment risks [1] - Huazhong Securities disclaims any responsibility for losses incurred by individuals using the content of the meeting [1] Other Important but Possibly Overlooked Content - The call is governed by the Securities and Futures Investor Suitability Management Measures, indicating regulatory compliance [1]

Summary of the Earnings Call for Yinkang Life (2023) Company Overview - **Company**: Yinkang Life - **Date of Call**: April 22, 2024 - **Industry**: Healthcare, specifically focusing on medical services and medical devices Key Points Financial Performance - **Revenue**: Yinkang Life achieved a revenue of 1.47 billion (14.7 billion) in 2023, representing a year-on-year growth of 27.2%, which is the highest growth rate since 2019, surpassing the compound annual growth rate (CAGR) of 26.6% from 2019 to 2023 [5][6][10] - **Net Profit**: The company reported a net profit of 100 million (1 billion), a significant increase of 117% year-on-year, adjusted for commercial impairment [6][10] - **Quarterly Performance**: In Q4 2023, the medical services segment generated revenue of 286 million (2.86 billion), up 26.5% year-on-year, while the medical devices segment reported revenue of 83 million (830 million), a 16.4% increase [10][11] Business Segments - **Medical Services**: - Revenue from the medical services segment reached 1.15 billion (11.5 billion), exceeding pre-pandemic levels [8][10] - The number of surgeries performed reached 24,000, with over 70% being advanced surgeries [8][10] - The oncology segment's revenue was 1.26 billion (12.6 billion), accounting for 24% of total medical services revenue [15][16] - **Medical Devices**: - The medical devices segment achieved revenue of 320 million (3.2 billion), more than doubling year-on-year [9][10] - The integration of acquired companies, such as Shennuo, has strengthened operational capabilities [18][19] Strategic Initiatives - **High-Quality Development**: The company emphasized its commitment to high-quality development, focusing on enhancing operational efficiency and expanding its service offerings [4][5] - **Digital Transformation**: Yinkang Life plans to leverage digital technologies to improve service quality and operational efficiency, particularly in oncology services [17][34] - **Expansion Plans**: The company aims to increase its bed capacity and enhance its service capabilities, with a target of reaching 5,000 owned beds and over 1 million in revenue per bed within five years [36] Challenges and Responses - **Regulatory Environment**: The company is navigating a complex regulatory landscape, particularly concerning its fundraising efforts, with plans to complete a capital increase by mid-2024 [48][49] - **Operational Adjustments**: Adjustments in management and operational strategies are being implemented to address underperforming facilities, particularly in the Chongqing Youfang hospital [51][52] Market Outlook - **Growth Projections**: The company anticipates continued growth in both medical services and devices, with expectations for the medical services segment to maintain a growth rate of over 10% and the medical devices segment to exceed 50% [66] - **Focus on Oncology**: Yinkang Life is positioning itself as a leader in oncology services, aiming to enhance its brand recognition and service offerings in this specialty [27][31] Additional Insights - **Research and Development**: The company has significantly increased its R&D investment, with a focus on innovative medical devices and enhancing service capabilities [23][39] - **Talent Acquisition**: Yinkang Life is actively recruiting top talent and collaborating with leading medical institutions to strengthen its clinical capabilities [32][34] This summary encapsulates the key financial metrics, strategic initiatives, and market outlook for Yinkang Life as discussed in the earnings call, providing a comprehensive overview of the company's performance and future direction.

盈康生命科技股份有限公司 独立董事2023年度述职报告 各位股东及股东代表： 本人卢军作为盈康生命科技股份有限公司（以下简称"公司"）的第五届董事 会独立董事、战略与ESG委员会委员、提名委员会委员、薪酬与考核委员会主任委 员，在2023年1月1日至2023年9月28日任职期间严格按照《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司独立董事管理办法》《上市公司治理准则》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等 相关法律法规、规章制度以及《公司章程》《独立董事工作制度》的规定和要求， 在2023年度工作中，诚实、勤勉、独立的履行职责，积极出席相关会议，认真审议 董事会各项议案，对公司重大事项发表了事前认可意见及独立意见，充分发挥了独 立董事及各专门委员会委员的作用，切实维护了公司和股东特别是中小股东的利益， 较好的发挥了独立董事的独立性和专业性作用。现将2023年度本人履行独立董事职 责情况报告如下： 一、独立董事基本情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰 富的经验。本人个人工作履历、专业背景及兼职情况等相关情况如下： 卢军，19 ...

证券代码：300143 证券简称：盈康生命 公告编号：2024-018 （三）募集资金本报告期使用情况及结余情况 2023年1月1日至2023年12月31日（以下简称"本报告期"），公司实际使用募 集资金11,801,603.02元（其中：本报告期支付的银行手续费总额2,508.00元）。截至 2023年12月31日，募集资金余额为25,027,770.42元，募集资金使用情况如下： 盈康生命科技股份有限公司 关于 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）董事会根据中国证券监督管 理委员会颁布的《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监 管要求》和深圳证券交易所发布的《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等有关规定，编制了公司 2023 年度募集资金存放 与使用情况的专项报告。报告主要内容如下： 一、募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会《关于核准盈康生命科技股份有限公司非 ...

证券代码：300143 证券简称：盈康生命 公告编号：2024-020 盈康生命科技股份有限公司 就公司未分配利润为负的情况，公司董事会和管理层进行了认真总结，将从两 1 个方面改善公司的情况。 关于未弥补亏损达实收股本总额三分之一的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）于 2024 年 4 月 19 日召开第 六届董事会第七次会议，审议通过了《关于未弥补亏损达到实收股本总额三分之一 的议案》，本议案尚需提交公司 2023 年年度股东大会审议。现将具体情况公告如 下： 一、情况概述 根据和信会计师事务所（特殊普通合伙）出具的和信审字（2024）第 000241 号《审计报告》，截止 2023 年 12 月 31 日，公司 2023 年度合并财务报表中未分配 利润为-1,513,495,428.28 元，归属于上市公司股东的净利润为 100,436,255.25 元，公 司实收股本为 642,167,010.00 元，公司未弥补亏损金额超过实收股本总额三分之一。 根据《公司法》及《公司章程》的相关规定， ...

关于苏州广慈肿瘤医院有限公司 2023 年度 承诺业绩实现情况的鉴证报告 和信专字（2024）第 000179 号 | 目 录 | 页 | 码 | | --- | --- | --- | | 一、承诺业绩实现情况的鉴证报告 | 1-2 | | 二、承诺业绩实现情况的专项说明 和信会计师事务所（特殊普通合伙） 二〇二四年四月十九日 盈康生命科技股份有限公司 鉴证报告 关于苏州广慈肿瘤医院有限公司 2023 年度承诺业绩实现情况的鉴证报告 和信专字（2024）第 000179 号 盈康生命科技股份有限公司全体股东： 我们接受委托，对后附的盈康生命科技股份有限公司（以下简称"盈康生命"） 编制的《关于苏州广慈肿瘤医院有限公司 2023 年度承诺业绩实现情况的专项说 明》（以下简称"专项说明"）执行了鉴证工作。 一、盈康生命董事会的责任 盈康生命管理层的责任是参照中国证券监督管理委员会颁布的《上市公司重 大资产重组管理办法》编制专项说明，并保证其内容真实、准确、完整，以及不 存在由于舞弊或错误而导致的重大错报。 二、注册会计师的责任 我们的责任是在实施鉴证工作的基础上，对专项说明发表鉴证意见。我们按 照《中国注册会计 ...

盈康生命科技股份有限公司 独立董事2023年度述职报告 各位股东及股东代表： 本人唐功远作为盈康生命科技股份有限公司（以下简称"公司"）的第五届董 事会独立董事、审计委员会委员、提名委员会主任委员和战略与ESG委员会委员， 在任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司独立董事管理办法》《上市公司治理准则》《深圳证券交易所上市公司自律监 管指引第2号——创业板上市公司规范运作》等相关法律法规以及《公司章程》 《独立董事工作制度》的规定和要求，在2023年度工作中，诚实、勤勉、独立的履 行职责，积极出席相关会议，认真审议董事会各项议案，对公司重大事项发表了事 前认可意见及独立意见，充分发挥了独立董事及各专门委员会委员的作用，切实维 护了公司和股东特别是中小股东的利益，较好的发挥了独立董事的独立性和专业性 作用。现将2023年度本人履行独立董事职责情况报告如下： 一、独立董事基本情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰 富的经验。本人个人工作履历、专业背景及兼职情况等相关情况如下： 唐功远，1956年10月出生，中国国籍，有美国永久居留权，研究生学 ...